Adicet Bio Inc (ACET)

$0.80 -0.05 (-5.90%)
Market Cap 69.71M
Revenue (ttm) 0.00
Net Income (ttm) -142.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 438,800
Avg Vol 917,428
Day's Range N/A - N/A
Shares Out 82.40M
Stochastic %K 7%
Beta 1.97
Analysts Strong Sell
Price Target $7.00

Latest News on ACET

Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress

Mar 6, 2025, 4:01 PM EST - 2 days ago

Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress

Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting

Mar 3, 2025, 7:00 AM EST - 5 days ago

Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)

Feb 27, 2025, 7:00 AM EST - 9 days ago

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement

Feb 5, 2025, 7:10 AM EST - 4 weeks ago

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Jan 31, 2025, 6:06 PM EST - 5 weeks ago

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

Jan 29, 2025, 7:00 AM EST - 5 weeks ago

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones

Jan 8, 2025, 4:10 PM EST - 2 months ago

Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Dec 31, 2024, 4:48 PM EST - 2 months ago

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Dec 19, 2024, 7:00 AM EST - 2 months ago

Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer

Dec 18, 2024, 7:00 AM EST - 2 months ago

Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer

Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Nov 18, 2024, 4:00 PM EST - 3 months ago

Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

Nov 18, 2024, 7:00 AM EST - 3 months ago

Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

Nov 16, 2024, 9:00 AM EST - 4 months ago

Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 6, 2024, 4:00 PM EST - 4 months ago

Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates

Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024

Nov 5, 2024, 7:00 AM EST - 4 months ago

Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024

Adicet Bio to Participate in Upcoming Investor Conferences

Nov 1, 2024, 7:00 AM EDT - 4 months ago

Adicet Bio to Participate in Upcoming Investor Conferences

Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome

Oct 16, 2024, 7:00 AM EDT - 5 months ago

Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome

Adicet Bio to Present at the American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference

Sep 30, 2024, 4:30 PM EDT - 5 months ago

Adicet Bio to Present at the American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference

Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases

Sep 30, 2024, 7:00 AM EDT - 5 months ago

Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases

ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue

Sep 19, 2024, 7:00 AM EDT - 6 months ago

ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue

Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 27, 2024, 4:00 PM EDT - 6 months ago

Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors

Aug 19, 2024, 7:00 AM EDT - 7 months ago

Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors

Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 13, 2024, 7:00 AM EDT - 7 months ago

Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates

Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Jul 8, 2024, 7:00 AM EDT - 8 months ago

Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma

Jun 24, 2024, 7:00 AM EDT - 9 months ago

Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma

Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis

Jun 5, 2024, 7:00 AM EDT - 9 months ago

Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis

Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference

May 29, 2024, 7:00 AM EDT - 10 months ago

Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference

Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates

May 14, 2024, 4:01 PM EDT - 10 months ago

Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates

Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress

May 14, 2024, 10:00 AM EDT - 10 months ago

Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress

Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference

May 7, 2024, 7:00 AM EDT - 10 months ago

Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference

Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

Apr 22, 2024, 4:30 PM EDT - 11 months ago

Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference

Apr 8, 2024, 7:00 AM EDT - 11 months ago

Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference

Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

Mar 19, 2024, 4:10 PM EDT - 1 year ago

Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Mar 11, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Feb 5, 2024, 4:01 PM EST - 1 year ago

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Jan 25, 2024, 4:01 PM EST - 1 year ago

Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Adicet Bio, Inc. Announces Pricing of Public Offering

Jan 22, 2024, 11:43 PM EST - 1 year ago

Adicet Bio, Inc. Announces Pricing of Public Offering

Adicet Bio, Inc. Announces Proposed Public Offering

Jan 22, 2024, 4:28 PM EST - 1 year ago

Adicet Bio, Inc. Announces Proposed Public Offering

Adicet Bio: Clinical Updates In 2H 2024 Makes This A Must-Watch

Jan 8, 2024, 7:19 PM EST - 1 year ago

Adicet Bio: Clinical Updates In 2H 2024 Makes This A Must-Watch

Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024

Jan 4, 2024, 7:00 AM EST - 1 year ago

Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024

Adicet Bio to Host Conference Call to Provide Updates on its Clinical Pipeline and Corporate Outlook

Jan 3, 2024, 4:01 PM EST - 1 year ago

Adicet Bio to Host Conference Call to Provide Updates on its Clinical Pipeline and Corporate Outlook

Adicet Bio Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study at the 65th American Society of Hematology (ASH) Annual Meeting

Dec 10, 2023, 12:00 PM EST - 1 year ago

Adicet Bio Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study at the 65th American Society of Hematology (ASH) Annual Meeting

Adicet Reports Third Quarter 2023 Financial Results and Provides Business Updates

Nov 8, 2023, 4:10 PM EST - 1 year ago

Adicet Reports Third Quarter 2023 Financial Results and Provides Business Updates

Adicet Bio to Present at the 2023 Jefferies London Healthcare Conference

Nov 7, 2023, 7:00 AM EST - 1 year ago

Adicet Bio to Present at the 2023 Jefferies London Healthcare Conference

Adicet Bio Announces Poster Presentation Highlighting ADI-001 Data at the 65th American Society of Hematology (ASH) Annual Meeting

Nov 2, 2023, 9:00 AM EDT - 1 year ago

Adicet Bio Announces Poster Presentation Highlighting ADI-001 Data at the 65th American Society of Hematology (ASH) Annual Meeting

Adicet Bio Announces Poster Presentation at the Upcoming 2023 Molecular Targets and Cancer Therapeutics Conference

Oct 4, 2023, 12:00 PM EDT - 1 year ago

Adicet Bio Announces Poster Presentation at the Upcoming 2023 Molecular Targets and Cancer Therapeutics Conference

Adicet Bio to Present Three Scientific Posters Highlighting its Allogeneic Gamma Delta T Cell Platform and Programs at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Sep 27, 2023, 9:00 AM EDT - 1 year ago

Adicet Bio to Present Three Scientific Posters Highlighting its Allogeneic Gamma Delta T Cell Platform and Programs at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Adicet Reports Second Quarter 2023 Financial Results and Provides Business Updates

Aug 9, 2023, 4:15 PM EDT - 1 year ago

Adicet Reports Second Quarter 2023 Financial Results and Provides Business Updates

Adicet Bio to Participate in a Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference

Aug 2, 2023, 4:00 PM EDT - 1 year ago

Adicet Bio to Participate in a Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference